登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码:000623 证券简称:吉林敖东 公告编号:2025-057 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 重要内容提示： 1.董事会及董事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息 的真实、准确、完整。 3.第三季度财务会计报告是否经过审计 √适用 □不适用 单位：元 ■ □是 √否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 √否 ■ （二） 非经常性损益项目和金额 其他符合非经常性损益定义的损益项目的具体情况： □适用 √不适用 公司不存在其他符合非经常性损益定义的损益项目的具体情况。 将《公开发行证券的公司信息披露解释性公告第1号一一非经常性损益》中列举的非经常性损益项目界 定为经常性损益项目的情况说明 □适用 √不适用 公司不存在将《公开发行证券的公司信息披露解释性公告第 ...

Core Viewpoint - Jilin Aodong (000623.SZ) reported a year-on-year increase in revenue and net profit for Q3 2025, indicating positive financial performance and growth potential [1] Financial Performance - The company achieved an operating revenue of 5.139 billion yuan, representing a year-on-year increase of 3.25% [1] - The net profit attributable to shareholders reached 979 million yuan, showing a significant year-on-year increase of 38.53% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 823 million yuan, reflecting a substantial year-on-year increase of 109.71% [1] - Basic earnings per share were reported at 0.835 yuan [1]

Core Insights - The company reported a revenue of 1.64 billion yuan for the first three quarters of 2025, representing a year-on-year decline of 14.10% [1] - The net profit attributable to shareholders increased to 2.26 billion yuan, showing a significant year-on-year growth of 81.70% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses reached 1.99 billion yuan, reflecting a year-on-year increase of 65.20% [1] Financial Performance - Revenue for the first three quarters: 1.64 billion yuan, down 14.10% year-on-year [1] - Net profit attributable to shareholders: 2.26 billion yuan, up 81.70% year-on-year [1] - Net profit after deducting non-recurring items: 1.99 billion yuan, up 65.20% year-on-year [1]

证券代码：000623 证券简称：吉林敖东 公告编号：2025-058 吉林敖东药业集团股份有限公司 关于对外投资调整并引入战略投资者的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 吉林敖东药业集团股份有限公司（以下简称"公司"）于 2025 年 10 月 30 日召开第十一届董事会第十九次会议审议通过了《关于对外投资调整并引入战略 投资者的议案》，为适应市场变化，优化子公司敖东药业（安徽）股份有限公司 （以下简称"敖东安徽公司"）的资本结构与战略布局，经与控股子公司吉林敖 东延边药业股份有限公司（以下简称"延边药业"）协商，拟调整对外投资并引 进战略投资者，具体公告如下： 一、对外投资概述 本次对外投资调整涉及子公司注册资本变更及引入战略投资者，本次调整不 涉及关联交易，不构成《上市公司重大资产重组管理办法》规定的重大资产重组。 1.注册资本调整 敖东安徽公司注册资本由 30,000 万元减少至 2,000 万元，减资程序按照《公 司法》相关规定执行。 1 2.出资义务调整 公司：终止原计划未实缴的 300 万元出资义务，不再持有敖东安徽公司股份。 ...

证券代码：000623 证券简称：吉林敖东 公告编号:2025-056 吉林敖东药业集团股份有限公司 第十一届董事会第十九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、吉林敖东药业集团股份有限公司（以下简称"公司"）第十一届董事会 第十九次会议通知以书面方式于 2025 年 10 月 19 日发出。 2、会议于 2025 年 10 月 30 日在公司六楼会议室以现场结合通讯方式召开。 3、本次会议公司应到董事 9 名，实际参加会议董事 9 名，其中：独立董事 李鹏先生、肖维维女士、梁毕明先生以通讯表决方式出席本次会议。 4、会议由公司董事长李秀林先生主持，公司高级管理人员列席本次董事会 会议。 5、本次会议的召开符合有关法律、行政法规、部门规章、规范性文件和《公 司章程》的规定。 二、董事会会议审议情况 1、审议《公司 2025 年第三季度报告全文》 董事会经审议认为：《公司 2025 年第三季度报告全文》的编制程序、内容 以及格式符合相关法律、法规和中国证监会规范性文件的规定和要求；公司的 财务报告真实、准确、完 ...

Financial Performance - The company's revenue for Q3 2025 was ¥513,937,810.01, an increase of 3.25% compared to the same period last year[4] - Net profit attributable to shareholders reached ¥978,957,330.73, representing a significant increase of 38.53% year-on-year[4] - The net profit excluding non-recurring gains and losses was ¥823,238,943.93, up 109.71% from the previous year[4] - Basic earnings per share were ¥0.8350, reflecting a growth of 41.31% compared to the same quarter last year[4] - Net profit attributable to shareholders of the parent company rose to ¥2,260,496,439.24, an increase of 81.70% driven by investment income and fair value changes.[9] - Net profit for the current period is ¥2,255,329,694.19, compared to ¥1,218,546,029.35 in the previous period, indicating an increase of approximately 85.1%[19] - The profit attributable to shareholders of the parent company is ¥2,260,496,439.24, up from ¥1,244,115,685.35, marking a growth of around 81.7%[19] - The total comprehensive income for the current period is ¥2,195,731,865.17, compared to ¥1,457,427,889.24, indicating an increase of approximately 50.7%[19] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥34,575,899,940.55, a 4.77% increase from the end of the previous year[4] - The company's equity attributable to shareholders increased by 5.31% to ¥30,568,244,673.71 compared to the end of last year[4] - Total assets increased to $34.58 billion from $33.00 billion, representing a growth of approximately 4.8%[17] - Current assets rose to $5.22 billion, up from $4.83 billion, indicating an increase of about 8.1%[15] - Long-term equity investments increased to $25.73 billion from $24.35 billion, reflecting a growth of approximately 5.7%[15] - Total liabilities decreased slightly to $3.76 billion from $3.72 billion, a change of about 1.1%[17] - Short-term borrowings decreased to $1.14 billion from $1.25 billion, a reduction of approximately 9.0%[17] - Accounts payable decreased to $352.15 million from $417.39 million, a decline of about 15.6%[17] - Non-current assets totaled $29.36 billion, up from $28.17 billion, indicating an increase of about 4.2%[17] - The company's retained earnings increased to $21.46 billion from $19.78 billion, reflecting a growth of approximately 8.5%[17] Cash Flow - Cash flow from operating activities for the year-to-date was ¥161,051,103.70, showing a remarkable increase of 443.63%[4] - Operating cash flow net amount improved to ¥161,051,103.70, a substantial increase of 443.63% compared to the previous period.[9] - Cash inflow from operating activities totaled ¥1,846,002,397.37, down from ¥2,149,740,908.19, a decrease of about 14.1%[20] - Cash flow from operating activities decreased from 2,196,608,043.40 to 1,684,951,293.67, a decline of approximately 23.3%[22] - Cash flow from investment activities increased by 91.28% to ¥510,339,185.26, attributed to a decrease in cash paid for investments.[9] - Cash inflow from investment activities decreased from 3,822,068,687.00 to 2,788,846,709.32, representing a drop of about 27.1%[22] - Net cash flow from financing activities showed a negative change from -672,365,438.79 to -563,265,104.30, indicating an improvement of approximately 16.3%[22] - Total cash and cash equivalents at the end of the period increased to 1,213,726,929.22 from 1,105,646,454.39, reflecting a growth of about 9.8%[22] Expenses and Income - Management expenses decreased by 31.40% to ¥142,954,141.60, attributed to enhanced internal controls[8] - Financial expenses were reduced by 50.85% to ¥29,631,579.59, primarily due to a decrease in interest expenses[8] - Investment income increased to ¥2,080,922,165.92, a year-on-year growth of 58.63% primarily due to gains from investments in GF Securities Co., Ltd.[9] - Fair value changes in financial assets resulted in a profit of ¥292,443,572.99, reflecting a significant increase of 1358.96% compared to the previous period.[9] - Credit impairment losses decreased by 86.25% to ¥-1,511,287.29, mainly due to a reduction in expected credit losses on other receivables.[9] - The company reported a significant increase in prepayments by 92.21% to ¥50,113,850.22, mainly due to prepayments to suppliers[8] - The company reported a decrease in other comprehensive income after tax to ¥-59,597,829.02, a decline of 124.95% year-on-year.[9] - The net asset disposal loss decreased by 43.37% to ¥-265,374.22, indicating improved asset management.[9] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 61,216, with no preferred shareholders restoring voting rights.[11] - The largest shareholder, Dunhua Jincheng Industrial Co., Ltd., holds 27.35% of shares, amounting to 327,080,749 shares, with 107,425,000 shares pledged.[11]

Core Insights - The traditional Chinese medicine sector saw a slight increase of 0.25% on October 29, with Jilin Aodong leading the gains [1] - The Shanghai Composite Index closed at 4016.33, up 0.7%, while the Shenzhen Component Index closed at 13691.38, up 1.95% [1] Stock Performance - Jilin Aodong (000623) closed at 21.82, with a rise of 4.95% and a trading volume of 311,200 shares, amounting to a transaction value of 672 million yuan [1] - Other notable gainers included: - Biovale (920266) at 10.41, up 3.17% [1] - Datang Pharmaceutical (920433) at 6.74, up 2.90% [1] - Kang En Bei (600572) at 4.56, up 2.47% [1] - Baiyunshan (600332) at 26.12, up 2.15% [1] Capital Flow - The traditional Chinese medicine sector experienced a net outflow of 522 million yuan from institutional investors, while retail investors saw a net inflow of 560 million yuan [2][3] - The capital flow for key stocks showed: - Jilin Aodong had a net inflow of 75.01 million yuan from institutional investors [3] - Baiyunshan had a net inflow of 25.07 million yuan from institutional investors [3] - Zhenbao Island (603567) had a net inflow of 17.41 million yuan from institutional investors [3]

Core Viewpoint - Jilin Aodong reported that it uses the equity method for long-term equity investment accounting, calculating based on the net profit of GF Securities attributable to the parent company's shareholders after deducting perpetual bond interest [1] Summary by Relevant Sections Investment in GF Securities - As of December 31, 2024, the company and its wholly-owned subsidiaries hold a total of 1,528,087,767 shares of GF Securities, accounting for 20.0508% of GF Securities' total share capital [1] - GF Securities is expected to achieve a net profit attributable to listed company shareholders of 963,682.99 million yuan in 2024 [1] Investment Income - The investment income from GF Securities for the company is projected to be 174,940.45 million yuan, an increase from 124,343.52 million yuan in the same period last year, representing a year-on-year growth of 40.69% [1]

Core Insights - Levodopa is a key medication for treating Parkinson's disease, alleviating symptoms such as muscle stiffness, tremors, and slow movement. It also shows potential for treating Alzheimer's disease, chronic pain, and constipation, with broad applications in biomedical and materials science fields [1][3][4]. Industry Overview - The levodopa market has seen continuous growth in demand due to an aging population and increasing Parkinson's disease cases. The market was negatively impacted by the pandemic from 2020 to 2022, but sales began to recover in 2023, reaching 31.83 million yuan in 2024 [1][7][8]. Industry Chain - The levodopa industry chain consists of upstream suppliers of chemical raw materials and excipients, midstream research and manufacturing processes, and downstream applications in medical institutions, pharmacies, and patients. The number of Parkinson's patients significantly influences the industry's development, with over 3 million patients aged 65 and above in China [6][7]. Competitive Landscape - The global levodopa market is dominated by a few large pharmaceutical companies, such as Merck & Co. and Pfizer, while domestic companies primarily focus on generic drugs. Key players in China include Shandong Xinhua Pharmaceutical Co., Zhejiang Huahai Pharmaceutical Co., and others [8][9]. Industry Development Trends - Market demand for levodopa is expected to continue increasing due to the rising incidence of Parkinson's disease and improvements in healthcare systems in emerging countries [10]. - Technological advancements in biopharmaceuticals are likely to enhance levodopa production processes, leading to improved efficiency and product quality. Companies are expected to develop various formulations, such as sustained-release and controlled-release preparations, to enhance patient experience [11]. - The globalization of the levodopa industry presents opportunities for companies to expand into international markets, increasing brand recognition and competitiveness [12].

Core Viewpoint - Jilin Aodong announced the approval of "Naloxone Hydrochloride Injection" by the National Medical Products Administration, which is a significant development for the company and its subsidiary [2] Group 1 - Jilin Aodong's subsidiary, Jilin Aodong Pharmaceutical Group Yanji Co., Ltd., received the approval notification for the drug [2] - The approval is for a supplemental application for "Naloxone Hydrochloride Injection," indicating potential growth in the company's product offerings [2]